Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir plus rilpivirine long-acting into European clinical settings

C. Jonsson-Oldenbuettel; J. Ghosn; M. van der Valk; E. Florence; F. Vera; M. Ait-Khaled; G. Bontempo; C. Latham; C. A. Gutner; S. Iyer; R. DeMoor; M. Gill; M. Czarnogorski; J. van Wyk

Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir plus rilpivirine long-acting into European clinical settings

C. Jonsson-Oldenbuettel, J. Ghosn, M. van der Valk, E. Florence, F. Vera, M. Ait-Khaled, G. Bontempo, C. Latham, C. A. Gutner, S. Iyer, R. DeMoor, M. Gill, M. Czarnogorski, J. van Wyk

HIV/STI Clinic

Research output: Contribution to journal › Conference abstract in journal

Original language	English
Journal	Journal of the International AIDS Society
Volume	25
Pages (from-to)	241-242
Number of pages	2
ISSN	1758-2652
Publication status	Published - 2022

Cite this

Jonsson-Oldenbuettel, C., Ghosn, J., van der Valk, M., Florence, E., Vera, F., Ait-Khaled, M., Bontempo, G., Latham, C., Gutner, C. A., Iyer, S., DeMoor, R., Gill, M., Czarnogorski, M., & van Wyk, J. (2022). Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir plus rilpivirine long-acting into European clinical settings. Journal of the International AIDS Society, 25, 241-242.

Jonsson-Oldenbuettel, C. ; Ghosn, J. ; van der Valk, M. ; Florence, E. ; Vera, F. ; Ait-Khaled, M. ; Bontempo, G. ; Latham, C. ; Gutner, C. A. ; Iyer, S. ; DeMoor, R. ; Gill, M. ; Czarnogorski, M. ; van Wyk, J. / Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir plus rilpivirine long-acting into European clinical settings. In: Journal of the International AIDS Society. 2022 ; Vol. 25. pp. 241-242.

@article{35a89d3ad7804572ab8abc552b8e1067,

title = "Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir plus rilpivirine long-acting into European clinical settings",

author = "C. Jonsson-Oldenbuettel and J. Ghosn and {van der Valk}, M. and E. Florence and F. Vera and M. Ait-Khaled and G. Bontempo and C. Latham and Gutner, {C. A.} and S. Iyer and R. DeMoor and M. Gill and M. Czarnogorski and {van Wyk}, J.",

note = "CPDF",

year = "2022",

language = "English",

volume = "25",

pages = "241--242",

journal = "Journal of the International AIDS Society",

issn = "1758-2652",

publisher = "John Wiley & Sons",

}

Jonsson-Oldenbuettel, C, Ghosn, J, van der Valk, M, Florence, E, Vera, F, Ait-Khaled, M, Bontempo, G, Latham, C, Gutner, CA, Iyer, S, DeMoor, R, Gill, M, Czarnogorski, M & van Wyk, J 2022, 'Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir plus rilpivirine long-acting into European clinical settings', Journal of the International AIDS Society, vol. 25, pp. 241-242.

Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir plus rilpivirine long-acting into European clinical settings. / Jonsson-Oldenbuettel, C.; Ghosn, J.; van der Valk, M.; Florence, E.; Vera, F.; Ait-Khaled, M.; Bontempo, G.; Latham, C.; Gutner, C. A.; Iyer, S.; DeMoor, R.; Gill, M.; Czarnogorski, M.; van Wyk, J.

In: Journal of the International AIDS Society, Vol. 25, 2022, p. 241-242.

Research output: Contribution to journal › Conference abstract in journal

TY - JOUR

T1 - Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir plus rilpivirine long-acting into European clinical settings

AU - Jonsson-Oldenbuettel, C.

AU - Ghosn, J.

AU - van der Valk, M.

AU - Florence, E.

AU - Vera, F.

AU - Ait-Khaled, M.

AU - Bontempo, G.

AU - Latham, C.

AU - Gutner, C. A.

AU - Iyer, S.

AU - DeMoor, R.

AU - Gill, M.

AU - Czarnogorski, M.

AU - van Wyk, J.

N1 - CPDF

PY - 2022

Y1 - 2022

M3 - Conference abstract in journal

VL - 25

SP - 241

EP - 242

JO - Journal of the International AIDS Society

JF - Journal of the International AIDS Society

SN - 1758-2652

ER -